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ABSTRACT 
Objective: The aim of this work was preparing once daily mouth disintegrating tablets to handle easily for adult hypertensive patients who have 
difficulty in swallowing.  
Methods: Imidapril mouth dissolving tablets (MDTs) were prepared by direct compression method using different concentrations of synthetic 
super disintegrants namely Sodium starch glycolate, Croscarmellose sodium & Kyron T-314. The prepared tablets were evaluated for weight 
variation, thickness, hardness, friability, content uniformity, disintegration time and In-vitro dissolution studies. 
Results: The micropolitics study indicates that all formulations were of acceptable to good flowability. Tablet hardness and friability indicated that 
the prepared formulations were having good mechanical strength. The most satisfactory formulation F5 containing Sodium starch glycolate showed 
minimum disintegration time of 19 s and released a maximum amount of drug in 30 min in phosphate buffer 6.8pH, by an appropriate combination 
of excipients. The optimized F5 formulation containing Sodium starch glycolate was found to be stable during stability studies conducted for 3 mo 
as per International Conference on Harmonization (ICH) guidelines.  
Conclusion: The present study conclusively proved that Imidapril MDTs could be successfully developed using various super disintegrants. The 
prepared tablets gave promising results with respect to the faster release of Imidapril. Further clinical studies are suggested to confirm the ability of 
the best-achieved system to avoid the first pass metabolism of Imidapril and improve patient compliance. 
Keywords: Imidapril, Mouth dissolving tablets, Sodium starch glycolate, Croscarmellose sodium, Kyron T314. 
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INTRODUCTION 
For the past one decade, there has been an enhanced demand for 
more patient-friendly and compliant dosage forms. As a result, the 
demand for developing new technologies has been increasing 
annually [1]. One study showed that approximately 26% of 1576 
patients do not take their prescribed medication as they 
encountered problems when swallowing conventional tablets. To 
develop a chemical entity, a lot of money, hard work and time are 
required. So the focus is rather being laid on the development of new 
drug delivery systems for already existing drugs, with enhanced 
efficacy and bioavailability, thus reducing the dose and dosing 
frequency to minimize the side effects [2]. Recently the European 
Pharmacopoeia adopted the term oro-dispersible tablet as a tablet 
to be placed in the mouth where it disperses rapidly before 
swallowing and which disintegrates in less than 3 min [3]. When put 
in the mouth, these dosage forms disintegrate instantly to release 
the drug, which dissolves or disperses in the saliva. Thereafter, the 
drug may get absorbed from the pharynx and esophagus or from 
other sections of the gastrointestinal tract (G. I. T) as the saliva 
travels down. In such cases, bioavailability is significantly greater 
than that observed from conventional tablet dosage form [4-6]. The 
target populations for MDTs are pediatric, geriatric, and bedridden 
or developmentally disabled patients. Patients with persistent 
nausea, who are traveling, or who have little or no access to water 
are also good candidates. The performance of MDTs depends on the 
technology used in their manufacture. The orally disintegrating 
property of these tablets is attributable to the quick ingress of water 
into the tablet matrix, which creates porous structure and results in 
rapid disintegration. Hence, the basic approach to developing MDTs 
include maximizing the porous structure of the tablet matrix, 
incorporating the appropriate disintegrating agent and using water 
soluble excipients highly in the formulation [7]. 
Imidapril is an angiotensin-converting enzyme (ACE) inhibitor, used 
to treat hypertension and congestive heart failure. Imidapril lowers 
the production of angiotensin II, therefore relaxing arterial muscles 
while at the same time enlarging the arteries, allowing the heart to 
pump blood more easily, and more blood is pumped into and 
through larger passageways due to increasing blood flow. Imidapril 
has attaining various problems like difficulty in swallowing, less 
bioavailability, first pass metabolism in conventional dosage forms. 
Imidapril have a poor bioavailability of 28%-30%, the extent of 
absorption is not affected by the presence of food. However, the rate 
of absorption is reduced.  
The oral bioavailability of Imidapril can be enhanced by 
decreasing its extent of first pass effect. Mouth dissolving tablet 
formulation has been widely and successfully applied to improve 
the dissolution, solubility, and consequently the bioavailability of 
poorly water-soluble drugs. Because of its poor aqueous solubility, 
Imidapril may pose dissolution related absorption problem. The 
oral bioavailability of Imidapril can be enhanced by decreasing its 
extent of first pass effect.  
In the present study, an attempt had been made to prepare MDTs of 
Imidapril in the oral cavity with enhanced dissolution rate & hence 
improved patient compliance using different synthetic super 
disintegrants like Sodium starch glycolate, Cross carmellose sodium 
& Kyron T314 by applying direct compression technique which 
enhances the bioavailability of the drug by decreasing the 
disintegrating time and increase in drug release, and also to reduce 
the manufacturing cost, increase safety and reduces toxicity. From 
the literature survey, it was concluded that there is no formulation 
was made by using different synthetic super disintegrants in the 
formulation of Imidapril MDTs. 
MATERIALS AND METHODS 
Materials 
Imidapril was gifted by Hetero Drugs, Hyderabad. Sodium starch 
glycolate, Croscarmellose sodium was procured from Sanofi-Aventis 
Pvt. Ltd., Goa, Kyron T-314 was gifted by Corel Pharma Chem. Avicel 
pH101, Lactitol, Sodium Stearyl Fumarate, Talc, Neotame, Aerosil, 
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Orange Flavour were procured from S. D. Fine Chemicals, Mumbai, 
India. Remaining all other ingredients used was of analytical grade. 
Methods 
Calibration curves for the estimation of Imidapril 
Accurately weighed amount (100 mg) of the drug was dissolved in 
phosphate buffer of pH 6.8 in 100 ml volumetric flask and the 
volume was made up to 100 ml. From this stock solution 10 ml is 
withdrawn into a volumetric flask, made the volume up to 100 ml 
with phosphate buffer of pH 6.8. From this 2nd
Imidapril MDTs were prepared by direct compression method using 
super disintegrants like Sodium starch glycolate, Croscarmellose 
sodium& Kyron T314 in different proportion and in different 
combination. All the ingredients were accurately weighed and sifted 
through sieve no. #100.  
 stock solution 
(100mcg/ml), concentrations of 5, 10, 15, 20, 25, 30, µg/ml solutions 
were prepared and the corresponding absorbance was measured at 
231 nm in Ultraviolet-visible (UV-Visible) spectrophotometer. 
Precompression parameters for powder blend of Imidapril 
The powder blend of Imidapril were evaluated for various pre-
compression parameters such as angle of repose, bulk density, 
tapped bulk density, compressibility index & hausner’s ratio [8].  
Preparation of Imidapril tablets 
The drug, super disintegrants, avicel pH101, lactitol were triturated 
well in a mortar using pestle for 10 to 15 min. Then sodium stearyl 
fumarate, talc, aerosol, neotame and orange flavor were passed 
through sieve no. #100 blended well with the initial mixture. The 
final powder blend was compressed using 12 station tablet 
compression machine to produce oval-shaped tablets of Imidapril 
weighing 150 mg having a diameter of 8.5*3 mm. 
Post compression parameters of Imidapril tablets 
Size and shape 
The size and shape of the tablet can be dimensionally described, 
monitored and controlled [9]. 
Tablet thickness 
Tablet thickness is an important characteristic in reproducing 
appearance and also in counting by using the filling equipment. 10 
tablets were taken and their thickness was measured using Vernier 
calipers [10]. 
Weight variation 
Twenty tablets are taken and their weight is determined individually 
and collectively on an electronic weighing balance. The average 
weight of one tablet was determined from the collective weight. The 
weight variation test would be a satisfactory method of determining 
the drug content uniformity. 
 





















F1 10 1.5   75 56.5 2 2 1.5 0.5 1 
F2 10 3   75 55 2 2 1.5 0.5 1 
F3 10 4.5   75 53.5 2 2 1.5 0.5 1 
F4 10 6   75 52 2 2 1.5 0.5 1 
F5 10 7.5   75 50.5 2 2 1.5 0.5 1 
F6 10  1.5  75 56.5 2 2 1.5 0.5 1 
F7 10  3  75 55 2 2 1.5 0.5 1 
F8 10  4.5  75 53.5 2 2 1.5 0.5 1 
F9 10  6  75 52 2 2 1.5 0.5 1 
F10 10  7.5  75 50.5 2 2 1.5 0.5 1 
F11 10   1.5 75 56.5 2 2 1.5 0.5 1 
F12 10   3 75 55 2 2 1.5 0.5 1 
F13 10   4.5 75 53.5 2 2 1.5 0.5 1 
F14 10   6 75 52 2 2 1.5 0.5 1 
F15 10   7.5 75 50.5 2 2 1.5 0.5 1 
 
Tablet hardness 
The hardness of the tablet of each formulation was determined using 
Monsanto hardness tester or Pfizer hardness tester [11]. 
Friability 
The Friability of tablets was performed in a Roche Friabilator. It 
consists of a plastic chamber that revolves at 25 rpm. About ten 
tablets were weighed together and then placed in the chamber. The 
friabilator was operated for 100 revolutions, and the tablets were 
subjected to the combined effects of abrasion and shock because the 
plastic chamber carrying the tablets drops them at a distance of six 
inches with every revolution. The tablets are then dusted and re-
weighed. 
 
W1 = Initial weight of the 20 tablets, W2 = Weight of the 20 tablets 
after testing. 
Wetting time of tablets 
Five circular tissue papers of 10 cm diameter are placed in a petri-
dish with a 10 cm diameter. Ten millimeters of water-containing 
Eosin, a water-soluble dye, is added to petri-dish. A tablet is 
carefully placed on the surface of the tissue paper. The time required 
for water to reach the upper surface of the tablet is noted as a 
wetting time [12]. 
Water absorption ratio 
A piece of tissue paper folded twice was placed in a small petri-dish 
containing 6 ml of water. A tablet was put on the paper and time 
required for complete wetting was measured.  
The wetted tablet was then weighed. Water absorption ratio, R was 
determined using following equation [13]. 
R = 100 (Wa–Wb)/Wb  
Wb–weight of tablet before absorption 
Wa–weight of tablet after absorption 
In-vitro dispersion time 
One tablet was placed in a beaker containing 10 ml of pH 6.8 
phosphate buffers at 37±0.5 °C and the time required for complete 
dispersion was determined [14]. 
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Disintegration time 
The disintegration test was carried out using disintegration test 
apparatus. Six tablets were placed individually in each tube of 
disintegration test apparatus and discs were placed over each tablet. 
Distilled water was used as the medium maintained at 37 °C±0.5 °C 
and the time taken for each tablet to disintegrate completely was 
recorded. 
Uniformity of drug content 
Twenty tablets from each batch were weighed accurately and 
powdered. An amount of powder equivalent to 50 mg of the drug 
was transferred into a 100 ml volumetric flask. The volume was 
made with 6.8 pH phosphate buffer and sonicated for 10 min. The 
resulting solution was filtered and assayed at 231 nm using 
Ultraviolet spectrophotometer and drug content per tablet was 
determined. 
In-vitro dissolution profile 
In-vitro drug release study was performed at 37±0.5 °C using United 
States Pharmacopeia (USP) type-II apparatus with paddle rotating at 
50 rpm. The drug release study was carried out in saline Phosphate 
buffer pH 6.8 by taking about 500 ml of the dissolution medium. 
About 5 ml of sample was withdrawn at specified time intervals 
from the dissolution medium and replaced with equal volume of 
fresh medium. Samples were filtered through Whatman filter paper 
and analyzed using Ultraviolet spectrophotometer (UV-1700, 
Shimadzu Corporation, Japan) at 231 nm. 
Kinetics of drug release 
In order to examine the release mechanism of the drug from the 
tablets, the In-vitro drug release data of the mouth dissolving tablets 
were subjected to following release models zero order, first order 
models. 
Accelerated stability studies 
Stability studies were carried out on optimized formulation. The 
tablets were stored at 40 °C and 75% (relative humidity) RH for a 
duration of three months. After every one-month samples were 
withdrawn and tested for various parameters like hardness, drug 
content and in vitro drug release. 
RESULTS  
A successful attempt has been made to formulate Mouth dissolving 
tablets of Imidapril using three different super disintegrants namely 
Sodium starch glycolate, Croscarmellose sodium & Kyron T314 in 
five different concentrations (1%, 2%, 3%, 4% and 5%).  A total 
fifteen formulations were prepared. The effect of type and 
concentration of super disintegrants on the in-vitro release of the 
drug were studied and promising formulations were tested for in-
vivo efficacy. 
Calibration curves for Imidapril 
Calibration curve For Imidaprilat 231 nm in 6.8 pH phosphate buffer 
was shown in fig 1.  
 
 
Fig. 1: Calibration curve for Imidapril 
 
Pre-compression parameters  
Angle of repose  
The frictional forces in loose powder or granules can be measured 
by the angle of repose. The angle of repose values lies in the range of 
24 °.44'±0.01 to 30 °.09'±0.06. The outcomes were tabulated and 
data demonstrated in table 2. 
Bulk density and tapped density 
Both bulk density (BD) and tapped density (TD) were determined. 
Bulk density and tapped density showed values in the range of 
0.43±0.10g/cm3 to 0.58±0.45g/cm3and 0.48±0.12g/cm3 to 
0.67±0.14g/cm3
Carr’s Index was found to be in the range of 10.34±0.08% to 
15.09±0.02%. The outcomes were tabulated, and data demonstrated 
in table 2.  
 respectively. The tabulated results were shown in 
table 2. 
Carr’s Index  
 
Table 2: Flow properties of the blend 
Formula Bulk density  
(g/cm3
Tapped density  
(g/cm) 3
Angle of repose (θ) 
) 
Carr’s index (%) Hausners ratio 
F1 0.45±0.01 0.53±0.05 26°.81'±0.30 15.09±0.02 1.17±0.06 
F2 0.48±0.12 0.55±0.04 29°.30'±0.12 12.72±0.08 1.14±0.02 
F3 0.43±0.10 0.48±0.12 29°.71'±0.23 10.41±0.06 1.11±0.04 
F4 0.56±0.01 0.63±0.13 27°.55'±0.01 11.11±0.04 1.12±0.10 
F5 0.53±0.05 0.62±0.09 28°.47'±0.02 14.51±0.05 1.16±0.03 
F6 0.48±0.02 0.56±0.08 27°.63'±0.03 14.28±0.02 1.16±0.04 
F7 0.49±0.06 0.57±0.02 28°.45'±0.01 14.03±0.01 1.16±0.08 
F8 0.56±0.06 0.65±0.08 26°.31'±0.06 13.84±0.09 1.16±0.11 
F9 0.52±0.08 0.58±0.04 30°.04'±0.02 10.34±0.08 1.11±0.01 
F10 0.55±0.07 0.62±0.08 24°.44'±0.01 11.29±0.03 1.12±0.06 
F11 0.52±0.45 0.61±0.14 26°.32'±0.06 14.75±0.04 1.17±0.05 
F12 0.49±0.45 0.57±0.14 28°.01'±0.02 14.03±0.02 1.16±0.07 
F13 0.56±0.45 0.65±0.14 29°.05'±0.01 13.84±0.08 1.16±0.02 
F14 0.58±0.45 0.67±0.14 30°.09'±0.06 13.43±0.10 1.15±0.01 
F15 0.54±0.45 0.61±0.14 28°.89'±0.01 11.15±0.04 1.12±0.03 
All the values are expressed as mean±Standard deviation; n=3 
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Hausner’s ratio  
Hausner’s ratio was found in the range of 1.11±0.01 to 1.17±0.06. 
The results were tabulated and data shown in table 2. 
Post compressional parameters for Imidapril  
Hardness 
The hardness of the prepared tablet varied from 3.56±0.31to 
4.99±0.05 kg/cm2
In-vitro disintegration time was done by the USP dissolution 
apparatus. The disintegration rate has a correlation with water 
absorption capacity of disintegrate and the In-vitro disintegration 
time was found between 19 s to 52 s. The outcomes were tabulated 
and data demonstrated in table 3.  
 and the results were tabulated in table 3. 
Friability  
Friability was in the range of 0.36±0.05to 0.79±0.047 %. The 
outcomes were tabulated, and data demonstrated in table 3. 
Thickness  
The thickness of all the tablets was found to be between 2.24±0.037 
mm to 3.98±0.024 mm shown in table 3. 
Weight variation  
Weight variation of all the MDTs formulations were ranged from 
148±0.019 to 150±0.06 mg and the results were shown in table 3. 
Water absorption ratio and wetting time  
The Water absorption ratio founded between 58.2±0.1to 72.2±0.3 & 
wetting time of tablets were found between 22±0.6 s to 65±0.7 s. 
The outcomes were tabulated and shown in table 4. 
Dispersion time 
The dispersion time of all formulations was ranged from 1 min 2s to 
4 min 25s which were shown in table 4.  
Disintegration studies  
Drug content 
The percentage of drug content for all formulation was found to 
97.01±0.64% to 99.97±0.12 % as shown in table 4. Comparison of 
water absorption ratio, dispersion time & disintegration time of 
formulations for F5, F10 & F15 were shown in fig. 2. 
In-vitro dissolution studies 
In vitro dissolution studies of all the formulation were done for all 
formulations.  
Formulations F1, F2, F3, F4 & F5 which contained Sodium starch 
glycolate 1%, 2%, 3%, 4% and 5%w/w respectively, showed drug 
release of 35.47±0.02, 55.00±0.02, 73.34±0.01, 84.42±0.01 & 
98.14±0.01% and depicted in fig 3. 
Formulations F6, F7, F8, F9 & F10 which contained Croscarmellose 
sodium 1%, 2%, 3%, 4% and 5%w/w respectively, showed drug 
release of 43.00±0.02, 55.49±0.03, 67.69±0.0, 75.00±0.03, & 
92.15±0.04% and depicted in fig 4. 
Formulations F11, F12, F13, F14 & F15 which contained Kyron T314 
1%, 2%, 3%, 4% and 5%w/w respectively, showed drug release of 
42.58±0.02, 56.89±0.03, 67.37±0.03, 81.58±0.03 & 94.25±0.04% and 
depicted in fig 5.  
Comparison of dissolution profiles for formulations F5, F10& F15 
were shown in fig 6. 
Kinetic study 
Kinetic results revealed that the selected formulations followed first 
order kinetics as correlation coefficient (r2
 
) values are higher than 
that of zero order release kinetics. 
Table 3: Post compressional parameters of different formulations of Imidapril 
Formula Hardness kg/cm Friability2  Thickness(%)  Weight variation (mg) (mm) 
F1 4.99±0.05 0.38±0.01 2.97±0.041 150±0.027 
F2 4.96±0.08 0.61±0.02 3.08±0.019 148±0.019 
F3 4.01±0.09 0.49±0.05 3.98±0.024 149±0.029 
F4 3.94±0.03 0.36±0.05 3.05±0.031 150±0.059 
F5 4.05±0.08 0.50±0.002 2.24±0.037 150±0.047 
F6 3.56±0.31 0.41±0.012 3.04±0.025 149±0.032 
F7 3.99±0.42 0.45±0.021 2.96±0.022 150±0.060 
F8 3.85±0.41 0.56±0.031 3.01±0.031 148±0.024 
F9 4.40±0.49 0.71±0.024 2.94±0.037 149±0.039 
F10 4.12±0.35 0.58±0.012 2.96±0.025 150±0.025 
F11 4.23±0.39 0.39±0.012 3.09±0.031 149±0.044 
F12 4.19±0.29 0.68±0.024 3.04±0.031 150±0.034 
F13 3.98±0.31 0.55±0.031 2.99±0.041 150±0.014 
F14 3.91±0.42 0.79±0.047 2.95±0.016 150±0.016 
F15 4.31±0.41 0.62±0.023 3.02±0.041 150±0.024 
All the values are expressed as mean±Standard deviation; n=3 
 
 
Fig. 2: Comparison of water absorption ratio, dispersion time & disintegration time of formulations F5, F10 & F15, All values are 
expressed as mean±SD; (n=3) 
Vijaya et al. 
Int J Pharm Pharm Sci, Vol 8, Issue 1, 150-156 
154 
Table 4: Results of wetting time, water absorption ratio, dispersion time, disintegration time and drug content 
Formulation code Wetting time (sec) Water absorption ratio (%) Dispersion time  
(min: sec) 
Disintegration time (sec) Drug content (%) 
F1 48±0.1 58.2±0.1 3 min32 sec 52 98.16±0.25 
F2 45±0.3 60.5±0.6 2 min 55 sec 45 98.65±0.13 
F3 39±0.2 64.1±0.2 2 min 20 sec 36 97.01±0.64 
F4 29±0.3 66.5±0.7 1 min 48 sec 28 98.18±0.12 
F5 22±0.6 66±0.1 1 min 2 sec 19 99.97±0.12 
F6 58±0.5 60.4±0.9 4 min 25 sec 50 97.05±0.25 
F7 62±0.5 61.5±0.01 3 min 55 sec 42 99.16±0.31 
F8 60±0.7 64.7±0.4 3 min 59 sec 38 98.71±0.21 
F9 63±0.6 68.5±0.3 1 min 57 sec 31 99.40±0.41 
F10 59±0.7 70.8±0.1 1 min 34 sec 28 98.67±0.17 
F11 60±0.04 58.3±0.5 4 min 15 sec 48 99.12±0.19 
F12 62±0.03 61.0±0.7 3 min 16 sec 39 98.99±0.13 
F13 64±0.01 64.3±0.2 2 min 58 sec 33 99.55±0.12 
F14 63±0.2 65.1±0.05 2 min 15 sec 27 97.25±0.43 
F15 65±0.7 72.2±0.3 1 min 37 sec 24 98.99±0.25 
All the values are expressed as mean±Standard deviation; n=3 
 
 
Fig. 3: In-vitro drug release of Imidapril formulations from F1-F5, All values are expressed as mean±SD; (n=3) 
 
 
Fig. 4: In-vitro drug release of Imidapril formulations from F6-F10, All values are expressed as mean±SD; (n=3) 
 
 
Fig. 5: In-vitro drug release of Imidapril formulations from F11-F15, All values are expressed as mean±SD; (n=3) 
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Fig. 6: Comparison of dissolution profiles for formulations F5, F10 & F15, All values are expressed as mean±SD; (n=3) 
 
Table 5: Stability study results for F5 formulation 
Parameters tested Storage conditions 
Initial 40 °C±2 °C/75%±5% RH 
1st 2 month nd 3 month rd month 
Description White oval shaped tablets No change No change No change 
Average weight (mg) 150±0.047 150±0.046 150±0.035 150±0.013 
Thickness (mm) 2.24±0.037 2.24±0.031 2.24±0.020 2.24±0.002 
Hardness (kg/cm2 4.05±0.08 ) 4.05±0.02 4.05±0.02 4.05±0.00 
% Friability 0.50±0.0002 0.50±0. 0002 0.49±0.009 0.48±0.012 
Disintegration time (sec) 19s 17s 17s 17s 
Assay 99.85±0.12 99.25±0.18 99.20±0.21 99.00±0.12 
All values are expressed as mean±SD; (n=3) 
 
Stability studies 
The formulation F5 was selected for stability studies on the basis of 
high wetting time, absorption ratio, in vitro disintegration time and 
high cumulative % drug release. The accelerated stability studies 
were carried out at 40 °C/75 % RH for the selected formulation up 
to 90 d. For every 30 d time interval the tablets were analyzed for 
drug average weight, thickness, hardness, friability, assay, and in 
vitro disintegration time for up to 90 d. The formulations did not 
show much variation in any of the parameters. F5 was loaded for 
accelerated stability study at 40±2 °C/75±5 % RH. The results of 
stability data for 1st and 2nd month and 3rd
DISCUSSION 
 month (40±2 ° C/75±5 % 
RH) were found to be good shown in table 5. 
In this work MDTs were prepared by direct compression method by 
using different synthetic super disintegrants. The angle of repose 
values falling in the official limit range of 24 to 30 which indicates 
that all the formulation blend have good flow property. The bulk 
density of the formulation blend plays an important role in the 
compression of the powder. It was noted that the tapped density of 
all the formulation were greater than their respective bulk density 
thus indicating that all the powder formulation had a good 
compressibility. Carr’s index was calculated on the basis of the bulk 
and tapped density and the results showed good flow properties. 
Hausner’s ratio is a ratio between tapped and bulk density thus 
indicating that formulation blend has a free flowing property which 
is ideal for MDTs. 
All the formulated tablets passed weight variation test as the 
percent weight variation was within the pharmacopoeial limits [2]. 
The percent weight deviation was in between 5% of the average 
weight. The weights of all the tablets were found to be uniform with 
low standard deviation values. The crushing strength of the tablets 
of ensures good handling characteristics of all batches. The percent 
friability of all the formulation was less than 1% ensuring that the 
tablets were mechanically stable. Wetting time is closely related to 
the inner structure of the tablet and hydrophilicity of its excipients. 
Out of all the formulations, sodium starch glycolate containing 
formulations F1, F2, F3, F4, F5 showed less wetting time 48±0.1s, 
45±0.3s, 39±0.2s, 29±0.3s, & 22±0.6 s respectively, its disintegration 
action is by rapid wicking, swelling followed by disintegration. In all 
formulations, it was observed that wetting time decreased with 
increase in the concentration of super disintegrants. Water 
absorption ratio, which is an important criterion for understanding 
the capacity of disintegrants to swell in the presence of a little 
amount of water, was calculated. It was found to be in the range of 
58.2±0.1 to 72.2±0.3. The water absorption ratio increased with 
increase in the concentration of super disintegrant from 1-5%. This 
increase was due to the water up-taking ability of the super 
disintegrants. More the super disintegrant concentration, greater 
was the water uptake and hence, an increase in water absorption. 
The percentage of drug content for all formulation lies in the USP 
limit for MDT formulation of 90 to 110 % which was taken into 
consideration [7]. 
The internal structure of the tablets that is pore size distribution, 
water penetration into tablets and swelling of disintegrants are 
suggested to be the mechanisms of disintegration. Among the three 
super disintegrants used, sodium starch glycolate showed less 
disintegration time followed by Croscarmellose sodium and finally 
Kyron T314. It was also observed that the tablets with the least 
wetting time showed minimum disintegration time indicating a 
correlation between wetting time and disintegration time.  
The dissolution rate was found to be increased linearly with 
increase in the concentration of super disintegrant. The investigated 
super disintegrants can be ranked based on the overall in-vitro 
release profile of Imidapril Mouth dissolving tablet i.e. Sodium 
starch glycolate>Kyron T314>Croscarmellose sodium.  
CONCLUSION 
In the current study, a successful attempt was made to formulate 
mouth dissolving tablets of Imidapril by direct compression method 
using super disintegrants like Sodium starch glycolate, 
Croscarmellose sodium & Kyron T314. Preformulation studies of 
Imidapril were performed. Precompression parameters showed 
good flow property. The formulated tablets showed compliance for 
various physicochemical properties such as thickness, hardness, 
friability, content uniformity and in-vitro disintegration test. 
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The tablets containing synthetic super disintegrants have shown 
improved in-vitro disintegration time and drug release. The 
disintegration time for the optimized formula F5 was found to be 
19s. In-vitro release of the optimized formulation of Imidapril MDTs 
of F5 was found to be 98.14% drug release within 30 min. Data 
analysis for the order of drug release revealed formulations followed 
first order release. Accelerated stability studies for best-selected 
formulation F5 showed good physicochemical stability for a period 
of 90 d at 40 °C±2 and 75%RH. Selected MDTs were found to be 
stable with respect to physicochemical and release characteristics. 
Hence, MDTs containing Imidapril showed promising results. 
Further investigation can be made by using suitable animal model. 
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